ATE267198T1 - Synthese und anti-hiv und anti-hepatitis virus aktivität von 1,3-oxaselenolan nucleosiden - Google Patents
Synthese und anti-hiv und anti-hepatitis virus aktivität von 1,3-oxaselenolan nucleosidenInfo
- Publication number
- ATE267198T1 ATE267198T1 AT98914266T AT98914266T ATE267198T1 AT E267198 T1 ATE267198 T1 AT E267198T1 AT 98914266 T AT98914266 T AT 98914266T AT 98914266 T AT98914266 T AT 98914266T AT E267198 T1 ATE267198 T1 AT E267198T1
- Authority
- AT
- Austria
- Prior art keywords
- hiv
- synthesis
- hepatitis virus
- virus activity
- oxaselenolane
- Prior art date
Links
- 239000002777 nucleoside Substances 0.000 title abstract 2
- NCGOSRQTWABFIL-UHFFFAOYSA-N 1,3-oxaselenolane Chemical compound C1C[Se]CO1 NCGOSRQTWABFIL-UHFFFAOYSA-N 0.000 title 1
- 241000700605 Viruses Species 0.000 title 1
- 230000036436 anti-hiv Effects 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 208000006454 hepatitis Diseases 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- -1 1,3-oxaselenolane nucleoside Chemical class 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D421/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms
- C07D421/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings
- C07D421/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4126597P | 1997-03-19 | 1997-03-19 | |
| PCT/US1998/005517 WO1998041522A1 (en) | 1997-03-19 | 1998-03-19 | Synthesis, anti-human immunodeficiency virus and anti-hepatitis b virus activities of 1,3-oxaselenolane nucleosides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE267198T1 true ATE267198T1 (de) | 2004-06-15 |
Family
ID=21915638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98914266T ATE267198T1 (de) | 1997-03-19 | 1998-03-19 | Synthese und anti-hiv und anti-hepatitis virus aktivität von 1,3-oxaselenolan nucleosiden |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US6071922A (de) |
| EP (1) | EP0970078B1 (de) |
| CN (1) | CN1196701C (de) |
| AT (1) | ATE267198T1 (de) |
| AU (1) | AU739240B2 (de) |
| CA (1) | CA2287370C (de) |
| DE (1) | DE69823984T2 (de) |
| EA (2) | EA001920B1 (de) |
| ES (1) | ES2221164T3 (de) |
| WO (1) | WO1998041522A1 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE408410T1 (de) * | 1998-11-02 | 2008-10-15 | Gilead Sciences Inc | Kombinationstherapie zur behandlung von hepatitis b infektionen |
| NO20001904L (no) | 1999-04-14 | 2000-10-16 | Dow Chemical Co | Polyuretanfilmer fremstilt ved elektrolytisk utfelling fra polyuretandispersjoner |
| NO20001903L (no) | 1999-04-14 | 2000-10-16 | Dow Chemical Co | Polyuretan-filmer fremstilt fra polyuretan-dispersjoner |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| NZ547204A (en) | 2000-05-26 | 2008-01-31 | Idenix Cayman Ltd | Methods and compositions for treating flaviviruses and pestiviruses |
| CA2788498C (en) | 2001-03-01 | 2016-02-16 | Gilead Sciences, Inc. | Polymorphic and other crystalline forms of cis-ftc |
| US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| WO2005023274A1 (en) * | 2003-09-05 | 2005-03-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium |
| US7785839B2 (en) * | 2004-02-03 | 2010-08-31 | Emory University | Methods to manufacture 1,3-dioxolane nucleosides |
| WO2008030488A2 (en) | 2006-09-06 | 2008-03-13 | Med Institute, Inc. | Stents with connectors and stabilizing biodegradable elements |
| MX2012011222A (es) | 2010-04-01 | 2013-01-18 | Centre Nat Rech Scient | Compuestos y composiciones farmaceuticas para el tratamiento de infecciones virales. |
| KR101021294B1 (ko) * | 2010-10-11 | 2011-03-11 | 공주대학교 산학협력단 | 신규한 셀레닐 메틸 우라실 화합물 및 이를 이용한 방사선 치료 증진제 및 의약 조성물 |
| US9243025B2 (en) | 2011-03-31 | 2016-01-26 | Idenix Pharmaceuticals, Llc | Compounds and pharmaceutical compositions for the treatment of viral infections |
| WO2013039855A1 (en) | 2011-09-12 | 2013-03-21 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| SG11201703588SA (en) * | 2014-11-03 | 2017-05-30 | Nicolai Vladimirovich Bovin | Antimicrobial surface treatment |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223263A (en) * | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
| JPH02500017A (ja) * | 1986-09-30 | 1990-01-11 | ツアーンラートファブリーク、フリードリッヒスハーフェン、アクチエンゲゼルシャフト | ブレーキ一体形の走行車伝動装置 |
| NZ228645A (en) * | 1988-04-11 | 1991-09-25 | Iaf Biochem Int | 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections |
| US5466806A (en) * | 1989-02-08 | 1995-11-14 | Biochem Pharma Inc. | Processes for preparing substituted 1,3-oxathiolanes with antiviral properties |
| US5047407A (en) * | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
| US5041449A (en) * | 1988-04-11 | 1991-08-20 | Iaf Biochem International, Inc. | 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections |
| US5194654A (en) * | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
| US5463092A (en) * | 1989-11-22 | 1995-10-31 | Vestar, Inc. | Lipid derivatives of phosphonacids for liposomal incorporation and method of use |
| ES2106772T3 (es) * | 1989-12-20 | 1997-11-16 | Biotech Australia Pty Ltd | Variantes de pai-2. |
| US5728575A (en) * | 1990-02-01 | 1998-03-17 | Emory University | Method of resolution of 1,3-oxathiolane nucleoside enantiomers |
| US5204466A (en) * | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
| US6642245B1 (en) * | 1990-02-01 | 2003-11-04 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
| US5700937A (en) * | 1990-02-01 | 1997-12-23 | Emory University | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
| US5149794A (en) * | 1990-11-01 | 1992-09-22 | State Of Oregon | Covalent lipid-drug conjugates for drug targeting |
| US5543390A (en) * | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| US5256641A (en) * | 1990-11-01 | 1993-10-26 | State Of Oregon | Covalent polar lipid-peptide conjugates for immunological targeting |
| US5543389A (en) * | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization | Covalent polar lipid-peptide conjugates for use in salves |
| US5179104A (en) * | 1990-12-05 | 1993-01-12 | University Of Georgia Research Foundation, Inc. | Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides |
| US5925643A (en) * | 1990-12-05 | 1999-07-20 | Emory University | Enantiomerically pure β-D-dioxolane-nucleosides |
| WO1992010496A1 (en) * | 1990-12-05 | 1992-06-25 | University Of Georgia Research Foundation, Inc. | ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES |
| IL100965A (en) * | 1991-02-22 | 1999-12-31 | Univ Emory | 2 - Hydroxymethyl - 5 -) 5 - Fluorocytocin - 1 - Eyal (- 1, 3 - Oxathiolane, its resolution and pharmaceuticals containing it |
| AU662130B2 (en) * | 1991-03-06 | 1995-08-24 | Emory University | Use of 5-fluoro-2'-deoxy-3'-thiacytidine for the treatment of hepatitis B |
| GB9104740D0 (en) * | 1991-03-06 | 1991-04-17 | Wellcome Found | Antiviral nucleoside combination |
| WO1992018517A1 (en) * | 1991-04-17 | 1992-10-29 | Yale University | Method of treating or preventing hepatitis b virus |
| GB9110874D0 (en) * | 1991-05-20 | 1991-07-10 | Iaf Biochem Int | Medicaments |
| US5554728A (en) * | 1991-07-23 | 1996-09-10 | Nexstar Pharmaceuticals, Inc. | Lipid conjugates of therapeutic peptides and protease inhibitors |
| GB9116601D0 (en) * | 1991-08-01 | 1991-09-18 | Iaf Biochem Int | 1,3-oxathiolane nucleoside analogues |
-
1998
- 1998-03-19 WO PCT/US1998/005517 patent/WO1998041522A1/en active IP Right Grant
- 1998-03-19 EA EA199900843A patent/EA001920B1/ru not_active IP Right Cessation
- 1998-03-19 EP EP98914266A patent/EP0970078B1/de not_active Expired - Lifetime
- 1998-03-19 AT AT98914266T patent/ATE267198T1/de not_active IP Right Cessation
- 1998-03-19 CA CA2287370A patent/CA2287370C/en not_active Expired - Fee Related
- 1998-03-19 AU AU68665/98A patent/AU739240B2/en not_active Ceased
- 1998-03-19 ES ES98914266T patent/ES2221164T3/es not_active Expired - Lifetime
- 1998-03-19 DE DE69823984T patent/DE69823984T2/de not_active Expired - Lifetime
- 1998-03-19 EA EA200100494A patent/EA005097B1/ru not_active IP Right Cessation
- 1998-03-19 CN CNB988049341A patent/CN1196701C/zh not_active Expired - Fee Related
- 1998-03-19 US US09/044,558 patent/US6071922A/en not_active Expired - Fee Related
-
2000
- 2000-03-03 US US09/517,955 patent/US6197777B1/en not_active Expired - Fee Related
-
2001
- 2001-03-05 US US09/799,327 patent/US6590107B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2287370C (en) | 2010-02-09 |
| US6590107B1 (en) | 2003-07-08 |
| EA001920B1 (ru) | 2001-10-22 |
| EP0970078A1 (de) | 2000-01-12 |
| CA2287370A1 (en) | 1998-09-24 |
| ES2221164T3 (es) | 2004-12-16 |
| US6071922A (en) | 2000-06-06 |
| EA200100494A1 (ru) | 2001-10-22 |
| CN1196701C (zh) | 2005-04-13 |
| AU739240B2 (en) | 2001-10-04 |
| AU6866598A (en) | 1998-10-12 |
| DE69823984D1 (de) | 2004-06-24 |
| US6197777B1 (en) | 2001-03-06 |
| EP0970078B1 (de) | 2004-05-19 |
| EA005097B1 (ru) | 2004-10-28 |
| CN1255132A (zh) | 2000-05-31 |
| WO1998041522A1 (en) | 1998-09-24 |
| EA199900843A1 (ru) | 2000-04-24 |
| DE69823984T2 (de) | 2005-05-12 |
| EA200100494A3 (ru) | 2002-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69823984D1 (de) | Synthese und anti-hiv und anti-hepatitis virus aktivität von 1,3-oxaselenolan nucleosiden | |
| DE69635656D1 (de) | 5-fluoro-2',3'-ungesättigte pyrimidinnucleoside | |
| DE69232649T2 (de) | Verwendung von 5-fluoro-2'-deoxy-3'-thiacytidin zur behandlung von hepatitis b | |
| DK92788A (da) | Anvendelse af 3'-deoxy-3'-flourguanosider til fremstilling af laegemidler mod retrovira | |
| MA21560A1 (fr) | Nouvelles compositions comprenant des enzymes polymerises. | |
| DK0666749T3 (da) | Enantiomert rene beta-D-dioxalannukleosider med selektiv antihepatitis B virus aktivitet | |
| EP0984013A3 (de) | Antivirus Wirkung und Auflösung von 2-Hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane | |
| BR9815166A (pt) | "método de inibição da replicação de vìrus, composto, método de inibição da replicação de citomegalovìrus, composto antiviral, utilização de um composto, composição farmacêutica, composição farmacêutica inibidora da replicação de vìrus e de citomegalovìrus e composição farmacêutica antiviral" | |
| ITMI931522A1 (it) | Composizione farmaceutiche per il trattamento dell'infezione da virus dell'epatite b (hbv) | |
| MY107843A (en) | Anti-viral compounds. | |
| ES8802616A1 (es) | Un procedimiento para preparar una formulacion farmaceutica que contiene 3'-azido-3'-desoxitimidina o uno de sus derivados farmaceuticamente aceptables. | |
| GEP20084497B (en) | Hiv protease inhibitors | |
| DK0973735T3 (da) | Polyaromatiske antivirale præparater | |
| MY127808A (en) | Use of dideoxy nucleoside analogues in the treatment of viral infections | |
| TW371662B (en) | Antiviral acyclic phosphonomethoxyalkyl substituted alkenyl purine and pyrimidine derivatives | |
| MX9203217A (es) | Nucleosidos terapeuticos. | |
| DE69004451D1 (de) | Prophylaxe und Behandlung von Herpesvirus-Infektionen. | |
| BG102404A (en) | The application of flupirtin for the prevention and treatment of diseases related to impairement of the haematopoeic cellular system | |
| MY137298A (en) | Therapeutic nucleosides | |
| RU93058325A (ru) | Применение производных 1,3-оксатиолана для получения лекарственных препаратов для лечения или профилактики вирусной инфекции гепатита в, применение производных 1,3 - оксатиолана для лечения инфекций гепатита в, способ лечения гепатита в | |
| EP0316592A3 (de) | 3'-Fluor-2',3'-dideoxyuridin und seine therapeutische Verwendung | |
| ATE26267T1 (de) | Pyrimidin-derivate, ausgestattet mit antiviraler wirkung. | |
| MY113560A (en) | Use of 5-fluoro-2'-deoxy-3'-thiacytidine for the treatment of hepatitis b | |
| TW217986B (en) | Compositions for the treatment of infection and disease caused by HBV | |
| FR2652502B1 (fr) | Agent anti-virus du sida et medicaments therapeutiques ou preventifs utilisant cet agent. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |